Mark J. Ratain

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Tumour heterogeneity in the clinic

Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain et al. · Nature · 2013 · 1.2K citations · Full text

Medicine, Cancer Biology, Oncology +10

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2006 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan

Federico Innocenti, Samir D. Undevia, Lalitha Iyer et al. · Journal of Clinical Oncology · 2004 · 954 citations · Full text

Medicine, Oncology, Pharmacology +17

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

Jonas A. de Souza, Bonnie J. Yap, Kristen Wroblewski et al. · Cancer · 2016 · 882 citations · Full text

Medicine, Oncology, Chemotherapy +16